MedTrace Logo

Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections

NCT00417573 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2007-01-01

No results posted yet for this study

Summary

* This is the first study, that we are aware of, that will evaluate the efficacy of IgIV in patients with IgG subclass deficiency.
* Will provide data for further collaboration in extending study to involve other immunological centers in the United States to study patients with similar disease.

Conditions

Interventions

DRUG

IV Gamunex 10%

Sponsors & Collaborators

  • Grifols Therapeutics LLC

    collaborator INDUSTRY

  • The Center for Rheumatic Disease, Allergy, & Immunology

    lead OTHER

Principal Investigators

  • Nabih I Abdou, MD, PhD · Center for Rheumatic Disease, Allergy, Immunology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Completion
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00417573 on ClinicalTrials.gov